Deep Health Ai India Ltd vs Lincoln Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Deep Health AI India Ltd is ₹ 2.3 as of 18 May 15:30 . The P/E Ratio of Deep Health AI India Ltd changed from 65.7 on March 2024 to 24.9 on March 2025 . This represents a CAGR of -38.44% over 2 yearsThe P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 7.2 on March 2021 to 13.4 on March 2025 . This represents a CAGR of 13.23% over 5 years The Market Cap of Deep Health AI India Ltd changed from ₹ 18.91 crore on March 2024 to ₹ 14.34 crore on March 2025 . This represents a CAGR of -12.92% over 2 yearsThe Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 449.4 crore on March 2021 to ₹ 1104 crore on March 2025 . This represents a CAGR of 19.71% over 5 years The revenue of Deep Health AI India Ltd for the Dec '25 is ₹ 4.21 crore as compare to the Sep '25 revenue of ₹ 3.51 crore. This represent the growth of 19.94% The revenue of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 181.47 crore as compare to the Sep '25 revenue of ₹ 170.6 crore. This represent the growth of 6.37% The ebitda of Deep Health AI India Ltd for the Dec '25 is ₹ 3.67 crore as compare to the Sep '25 ebitda of ₹ 3.39 crore. This represent the growth of 8.26% The ebitda of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 38.74 crore as compare to the Sep '25 ebitda of ₹ 32.66 crore. This represent the growth of 18.62% The net profit of Deep Health AI India Ltd changed from ₹ 0.29 crore to ₹ 3.04 crore over 7 quarters. This represents a CAGR of 282.94% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 23.67 crore to ₹ 28.6 crore over 7 quarters. This represents a CAGR of 11.42% The Dividend Payout of Deep Health AI India Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 4.83 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of -1.94% over 5 years .

About Deep Health AI India Ltd

Deep Diamond India Limited was established in 1994, with the object to engaged in the manufacture and wholesale of gold set jewellery with diamonds.
The company also deals in loose diamonds, solitaires, and gold frames.
It offers Pendants, Nose pins, Rings, Bangles, Earrings, Pendant sets, Necklace sets, Bracelets, and others. From financial year 2022-23, the Company has also started business of providing consultancy service to Pharmaceutical Industry. During year 2023, Company diversified its business into pharmaceuticals business with professional management team at its Board.
Located in Mumbai, Deep Diamond India is a pharmaceutical company that focuses on developing and marketing innovative drugs and therapies to address unmet medical needs.
Their product portfolio includes prescription drugs, over-the-counter medicines, and medical devices.

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
All the assets and business of the erstwhile partnership were transferred to the Company.
The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

FAQs for the comparison of Deep Health AI India Ltd and Lincoln Pharmaceuticals Ltd

Which company has a larger market capitalization, Deep Diamond India Ltd or Lincoln Pharmaceuticals Ltd?

Market cap of Deep Diamond India Ltd is 33 Cr while Market cap of Lincoln Pharmaceuticals Ltd is 1,364 Cr

What are the key factors driving the stock performance of Deep Diamond India Ltd and Lincoln Pharmaceuticals Ltd?

The stock performance of Deep Diamond India Ltd and Lincoln Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Deep Diamond India Ltd and Lincoln Pharmaceuticals Ltd?

As of May 18, 2026, the Deep Diamond India Ltd stock price is INR ₹2.3. On the other hand, Lincoln Pharmaceuticals Ltd stock price is INR ₹681.05.

How do dividend payouts of Deep Diamond India Ltd and Lincoln Pharmaceuticals Ltd compare?

To compare the dividend payouts of Deep Diamond India Ltd and Lincoln Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.